SPECIAL ARTICLE: An Economic Evaluation of Activated Protein C Treatment for Severe Sepsis
17 June 2010
47 views
No Comment
Background: Recombinant human activated protein C was shown in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study to reduce mortality among patients with severe sepsis…. View full post on NEJM â Collection Updates for Critical Care |
Leave your response!
You must be logged in to post a comment.